Abstract
Population studies reveal HLA class I and class II gene polymorphisms associated with all the common chronic autoimmune diseases, notably spondylarthropathies, rheumatoid arthritis, multiple sclerosis and type I diabetes. We here discuss the exceptionally high levels of nucleotide diversity in the MHC region likely to reflect not only balancing selection acting on the epitope binding sites but also natural selection operating on the promoter region. The latter possibility is supported by functional studies with promoters, higher levels of diversity in the promoters of class II than class I genes and the relatively high frequency of single nucleotide polymorphisms around transcription factor binding sites. This, we argue, reflects the need for an appropriate level of signalling at the immunological synapse. We here summarise our knowledge of HLA promoter polymorphisms and how these translate into differential expression, T cell polarisation and inflammation. We discuss current strategies for pharmaceutical intervention in HLA expression.
Keywords: Promoter polymorphism, differential expression
Current Pharmaceutical Design
Title: The Role of HLA Promoters in Autoimmunity
Volume: 12 Issue: 29
Author(s): Brigitte Muller-Hilke and N. Avrion Mitchison
Affiliation:
Keywords: Promoter polymorphism, differential expression
Abstract: Population studies reveal HLA class I and class II gene polymorphisms associated with all the common chronic autoimmune diseases, notably spondylarthropathies, rheumatoid arthritis, multiple sclerosis and type I diabetes. We here discuss the exceptionally high levels of nucleotide diversity in the MHC region likely to reflect not only balancing selection acting on the epitope binding sites but also natural selection operating on the promoter region. The latter possibility is supported by functional studies with promoters, higher levels of diversity in the promoters of class II than class I genes and the relatively high frequency of single nucleotide polymorphisms around transcription factor binding sites. This, we argue, reflects the need for an appropriate level of signalling at the immunological synapse. We here summarise our knowledge of HLA promoter polymorphisms and how these translate into differential expression, T cell polarisation and inflammation. We discuss current strategies for pharmaceutical intervention in HLA expression.
Export Options
About this article
Cite this article as:
Muller-Hilke Brigitte and Mitchison N. Avrion, The Role of HLA Promoters in Autoimmunity, Current Pharmaceutical Design 2006; 12 (29) . https://dx.doi.org/10.2174/138161206778559759
DOI https://dx.doi.org/10.2174/138161206778559759 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Multilocular Thymic Cyst in a Patient with Untreated HIV/AIDS: Case Report
and Review of the Literature
Current HIV Research TNF-α and IL-6: The Link between Immune and Bone System
Current Drug Targets Editorial [Hot Topic : Graves Orbitopathy – A Therapeutic Challenge (Guest Editor: John H. Lazarus)]
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Naturally Occurring NF-κB Inhibitors
Mini-Reviews in Medicinal Chemistry Novel Coronavirus Disease (COVID-19): A Narrative Review Based on Current Status
Anti-Infective Agents Inhibitors of Myostatin- and Proteasome-Dependent Signaling for Attenuating Muscle Wasting
Recent Patents on Regenerative Medicine Modulation of Neutrophil Function by Hormones
Current Immunology Reviews (Discontinued) Preclinical Development of Novel Anti-Glioma Drugs Targeting the Endoplasmic Reticulum Stress Response
Current Pharmaceutical Design Subtype Selectivity in Phosphodiesterase 4 (PDE4): A Bottleneck in Rational Drug Design
Current Pharmaceutical Design Regulatory T Cells and Tolerogenic Dendritic Cells as Critical Immune Modulators in Atherogenesis
Current Pharmaceutical Design Actinic Keratosis Pathogenesis Update and New Patents
Recent Patents on Inflammation & Allergy Drug Discovery Recent Advances in the Development of Thioredoxin Reductase Inhibitors as Anticancer Agents
Current Drug Targets Regulation of Apoptosis and Cell Cycle Activity in Rheumatoid Arthritis
Current Molecular Medicine Biologics for Extraintestinal Manifestations of IBD
Current Drug Targets Patent Annotations
Recent Patents on Anti-Cancer Drug Discovery Glial Reaction in Parkinsons Diseases: Inflammatory Activation Signaling of Glia as a Potential Therapeutic Target
Current Signal Transduction Therapy Stroke Prevention in Patients with Non-valvular Atrial Fibrillation: New Insight in Selection of Rhythm or Rate Control Therapy and Impact of Mean Platelet Volume
Current Pharmaceutical Design Drug-Loaded Nanocarriers in Tumor Targeted Drug Delivery
Current Biotechnology Curcumin and Liver Cancer: A Review
Current Pharmaceutical Biotechnology Epidemiology of Spondyloarthritis in Asian Countries and Regions
Current Rheumatology Reviews